DPYSL3 and prostate cancer: In this study, we provided further evidences that DPYSL3 gene expression (variant 2 only) is significantly lower in primary prostate cancers than that in benign tissues and that CRMP4a protein levels are largely reduced in prostate cancers compared to the surrounding benign tissues.